Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...